Pith. sign in

REVIEW 5 major objections 7 minor 3 cited by

Predictive Significance of CD276/B7-H3 Expression in Baseline Biopsies of Advanced Prostate Carcinoma

T0 review · 5 major / 7 minor · reviewed 2026-08-05 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

Pith's one-line read Tumor B7-H3 measured in the baseline biopsy predicts shorter survival in metastatic prostate cancer.

desk verdict A replicative B7-H3 prognostic study that cannot be evaluated as written because the key hazard ratio is never actually reported. read the letter →

arxiv 2508.09373 v1 pith:G6LNNS7M submitted 2025-08-12 q-bio.QM stat.AP

Adam Yusuf , Paramahansa Pramanik This is my paper
classification q-bio.QMstat.AP
keywords prostatecancerCD276/B7-H3prognosticbiomarkerdiagnosticbiopsyimmunohistochemistrymetastaticsurvivalanalysisimmunecheckpoint
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

The paper argues that measuring membranous CD276/B7-H3 in the diagnostic biopsy, before any treatment begins, can identify which men with prostate cancer are already on a high-risk, fast-progressing course. In a retrospective cohort of 248 patients, 135 of whom had metastatic disease at presentation, tumors are classified as B7-H3 high when at least half of tumor cells show moderate-to-strong membranous staining. High B7-H3 correlates with higher PSA and more aggressive disease, and it predicts worse overall and cancer-specific survival even after adjusting for PSA, Gleason grade, age, and metastatic spread, with a reported hazard ratio greater than 2. If correct, this would give clinicians a biomarker available at diagnosis for early risk stratification and for selecting patients for B7-H3-targeted therapies. It also extends earlier B7-H3 findings from prostatectomy and localized disease to treatment-naive metastatic biopsies.

What carries the argument

The load-bearing measurement is B7-H3/CD276 membranous expression in archived treatment-naive needle biopsies, detected by a standardized immunohistochemistry protocol and scored independently by two pathologists blinded to outcome. Tumors are dichotomized as B7-H3 high when 50% or more of tumor cells show moderate-to-strong membranous staining. That binary status is then carried through Kaplan-Meier and log-rank survival analysis and multivariable Weibull and Cox regression with multiple imputation for missing clinical values; the multivariable survival models are what establish the claim of independence from PSA, Gleason grade, age, and metastatic distribution.

What would settle it

Rescore the 135 metastatic biopsies with the percentage of stained tumor cells treated as a continuous variable or with cutpoints other than 50%, then test the chosen cutpoint in a separate treatment-naive metastatic cohort using the same antibody, scoring rules, and multivariable adjustment; the central claim fails if the hazard ratio for high versus low B7-H3 is no longer clearly above 1 or is not stable across plausible cutpoints.

Watch

Extended reading notes

Core claim

On the authors' own account, the central discovery is that high membranous B7-H3 expression in baseline diagnostic biopsies is an independent prognostic marker in metastatic prostate cancer. In the metastatic subset, 41 of 135 patients were classified as B7-H3 high. These patients had higher median PSA (130 vs 95 ng/mL) and a higher frequency of Gleason grade 5 tumors. Kaplan-Meier estimates showed five-year overall survival of about 40% in the high group versus 62% in the low group, and disease-specific survival of 64% versus 86%; the survival gap was already visible at one year. In multivariable Weibull and Cox models adjusted for age, PSA, Gleason grade, and visceral metastases, high B7-H

Load-bearing premise

Everything rests on the rule that 'B7-H3 high' means at least half of tumor cells stain strongly; the authors themselves note that no consensus cutoff exists, and they neither optimize this threshold nor validate it in an external cohort.

Editorial extensions

If this is right

  • High B7-H3 at baseline biopsy separates a group of metastatic prostate cancer patients with markedly shorter survival, including a roughly 20-point gap in five-year overall survival.
  • B7-H3 status could be added to standard risk assessment at diagnosis, because the survival association persists after adjustment for PSA, Gleason grade, age, and metastasis.
  • Trials of B7-H3-targeted therapies, such as antibody-drug conjugates or CAR-T cells, could use baseline B7-H3 expression to enrich for patients most likely to progress and potentially respond.
  • The early divergence in survival curves implies that high B7-H3 patients may warrant intensified monitoring or earlier treatment decisions from the time of diagnosis.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • The paper leaves implicit a testable therapeutic prediction: if B7-H3 is an active driver rather than a correlate, biomarker-stratified trials randomizing high expressors to B7-H3 blockade should show a larger treatment effect in the high group; the current observational data cannot establish this.
  • The subgroup patterns, with a stronger effect in younger patients and in chemotherapy-treated patients, are hypothesis-generating rather than confirmatory given modest subgroup sizes; a prospective study with prespecified interaction tests and a uniform treatment protocol would be needed to make them actionable.
  • A natural extension would be to replace the 50% cutpoint with a continuous or algorithm-scored B7-H3 measure and compare discrimination against established tools; the paper reports no such head-to-head comparison.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

5 major / 7 minor

Summary. The paper retrospectively evaluates membranous CD276/B7-H3 expression by immunohistochemistry in diagnostic prostate biopsies from 248 men, including 135 with metastatic and 113 with localized disease. The authors report that high B7-H3 expression (≥50% moderate-strong membranous staining) is associated with higher PSA, more aggressive tumor features, and shorter overall and disease-specific survival. Survival analyses use Kaplan–Meier, log-rank, and Weibull/Cox multivariable models adjusted for age, PSA, Gleason grade, and metastatic spread. The paper claims that high B7-H3 remains a strong independent predictor of mortality with a hazard ratio 'greater than 2' and concludes that B7-H3 is a potent independent prognostic biomarker and potential therapeutic target in metastatic prostate cancer.

Significance. If the reported association is valid and reproducible, this study would address a genuine clinical gap: a biopsy-based prognostic marker applicable at diagnosis in advanced prostate cancer, with potential value for risk stratification and enrichment of trials of B7-H3-targeted therapies. The study has notable strengths: treatment-naïve baseline biopsies, independent blinded pathology review, multiple imputation for missing data, and combined nonparametric and parametric survival modeling. However, because the central multivariable effect is not reported with a point estimate, confidence interval, or event counts, and because the analysis cohort is ambiguously defined, the contribution cannot currently be evaluated. The clinical significance is real but contingent on transparent reporting and external validation.

major comments (5)
  1. [Section 3, quantitative results] The central claim of an 'independent' prognostic effect rests on a single sentence: 'high B7-H3 remained a strong predictor of mortality, with a hazard ratio greater than 2.' No point estimate, 95% confidence interval, exact p-value, event count, or regression table is provided for overall or disease-specific survival. This is not a stylistic omission; it makes the magnitude and precision of the adjusted effect impossible to assess. Please report full multivariable regression output (coefficient, SE, HR, CI, p-value) for OS and DSS, specify whether the 'greater than 2' result is from a Cox or Weibull model, and give the number of events in each B7-H3 group.
  2. [Table 1 and Figure 4] The sample size is not reconciled. The Abstract and Introduction state 248 men (135 metastatic, 113 localized), but Table 1 reports 135 total patients (94 low, 41 high) and Figure 4 is captioned 'among 135 patients.' If all survival analyses are restricted to the metastatic subgroup of 135, this must be stated explicitly, and the patient flow from 248 to 135 must be documented. The absence of this reconciliation obscures the statistical power and balance of the survival model, especially with only 41 high expressors and unknown numbers of deaths. Please also report the number of events and median follow-up for each B7-H3 stratum.
  3. [Section 2.1, B7-H3 cutoff] The 50% positivity threshold for defining high versus low B7-H3 is stated without justification, and the Introduction itself acknowledges that 'no consensus exists for defining high versus low B7-H3 expression.' The paper neither optimizes this cutoff nor validates it in an external cohort. Because the entire survival association is conditional on this binary split, a sensitivity analysis using alternative thresholds or a continuous staining score is essential. Without it, the reported HR 'greater than 2' may be threshold-dependent. The age (<70 vs ≥70) and chemotherapy subgroup splits also appear arbitrary and should be justified or treated as hypothesis-generating.
  4. [Declarations vs. Section 2.1] Section 2.1 states that the study 'received formal approval from our Institutional Review Board' with a waiver of informed consent, but the Declarations section states 'Not applicable' for ethics approval and consent. These statements are mutually contradictory. The ethics reporting must be corrected, and the relevant IRB approval number or institutional policy should be provided. This is a procedural issue that also undermines reader confidence in the reported data provenance.
  5. [Section 4, Discussion] The Conclusion states that the study 'establishes' B7-H3 as an independent prognostic biomarker, yet the Discussion acknowledges residual confounding from unmeasured comorbidities, lifestyle factors, and functional status, and states that 'we cannot entirely exclude the possibility that unmeasured confounders may have influenced the observed relationships.' Given the limited multivariable adjustment (four covariates), the absence of external validation, and the arbitrary cutoff, the strong causal language is not supported. Either temper the conclusion or provide additional evidence such as an E-value for unmeasured confounding or validation in an independent cohort.
minor comments (7)
  1. [Section 2.2] The sentence 'Schoenfeld residuals were (see figure 1) and formally tested' is incomplete. Please rephrase and describe how the residuals were used to assess proportional hazards.
  2. [Figures 1–4] Figure captions are incomplete. Please add axis labels, units, and legends. In particular, Figure 4(a) refers to '20 simulated PSA values missing among 135 patients'—clarify whether these are observed missing values or imputed simulations.
  3. [Table 1] The p-values are reported without stating the statistical test used for each row. Please specify the tests (e.g., Wilcoxon rank-sum for continuous, Fisher exact/chi-square for categorical) and report exact p-values rather than rounded cutoffs where possible.
  4. [Section 3] The text alternates between 'Weibull regression' and 'Cox models' without making clear which model generated the hazard ratio 'greater than 2.' Please clarify the model used for each reported result.
  5. [Section 2.1] The paper states that formal inter-observer agreement statistics were not calculated, but '100% consensus was achieved following discussion.' Given that two pathologists independently scored all samples, reporting Cohen's kappa or at least the distribution of initial disagreements would strengthen the reproducibility claim.
  6. [References] The reference list contains numerous self-citations to arXiv preprints and works in unrelated fields (e.g., soccer, turtle color patterns, pandemic control) that are cited as methodological support. These do not appear to substantiate the statistical or clinical choices in this paper. Please replace them with relevant methodological and clinical literature.
  7. [Data availability] The statement 'Data sets were obtained from institutional records' is not a data availability statement. Please clarify whether de-identified data can be shared and under what conditions.

Circularity Check

0 steps flagged · score 0.0 of 10

No significant circularity: the survival association is an in-sample statistical fit, not a derivation from its own inputs.

full rationale

The paper makes no formal derivation from first principles; it measures B7-H3 immunohistochemistry, dichotomizes expression at a 50% threshold, and tests survival associations. The central claim is a fitted multivariable association, so it cannot be circular in the sense of X deriving Y where X is defined by Y. The 50% cutpoint is arbitrary and the paper itself notes that no consensus cutoff exists and calls for external validation, but that is a validity/robustness limitation, not circularity. The Weibull 'predicted survival' curves are in-sample fitted curves and are presented as model outputs, not as independent predictions. Numerous self-citations (e.g., Pramanik and Polansky 2023a; Pramanik et al. 2025b) are attached to generic methods or to the conclusion, but none is load-bearing: the survival analysis, tables, and figures in the manuscript are the actual evidence. External citations (Amori et al. 2021, Inamura et al. 2018, Benzon et al. 2017) provide independent prior support for the B7-H3–prognosis link. No equation in the paper reduces to its own input, and no fitted parameter is renamed as a prediction. Residual confounding and the unreported HR/CI are correctness and reporting concerns, not circularity.

Assumptions & free parameters 2 free parameters · 6 assumptions · 0 invented entities

The central claim rests on the assumption that IHC detection, the 50% cutpoint, missing-data handling, and death registry linkage are all valid. None of these are independently verified in the paper, and the 50% cutpoint is imported from prior literature. The survival model parameters are fitted in the same sample used to define the groups.

free parameters (2)
  • B7-H3 high/low cutpoint = 50% of tumor cells with moderate-to-strong membranous staining
    The binary classification drives every survival comparison. The threshold is taken from Amori et al. (2021), not derived or validated here, so the reported hazard ratio is conditional on this choice.
  • Age subgroup cutpoint = 70 years
    Subgroup analyses partition the cohort at age 70. The choice is not justified by the data and affects the claim that younger patients show the strongest B7-H3 effect.
assumptions (6)
  • domain assumption Membranous B7-H3 measured by the BD/5A11 antibody on FFPE biopsy tissue corresponds to biologically relevant CD276 expression.
    The entire exposure definition rests on antibody specificity and staining fidelity; Section 2.1 states the protocol but supplies no validation data in this cohort.
  • domain assumption The 50% positivity threshold differentiates clinically meaningful high versus low B7-H3 groups.
    Section 2.1 fixes high at 50% or more tumor cells with moderate-to-strong staining; the paper acknowledges in the Introduction that no consensus cutoff exists.
  • domain assumption Missing clinical data are missing at random, making MICE imputation valid.
    Section 2.2 uses MICE and Little's MCAR test, but the MCAR result is not reported; unmeasured comorbidities are acknowledged as residual confounders in Section 4.
  • domain assumption The recorded cause of death and follow-up from registry and national death index are accurate.
    Survival endpoints (OS and DSS) depend on death registry linkage; Section 2.1 describes the source but no validation.
  • domain assumption The cohort is representative of the broader advanced prostate cancer population.
    Retrospective single-center design; Section 4 concedes generalizability is limited.
  • standard math Proportional hazards holds for the Weibull/Cox models.
    Schoenfeld residuals are mentioned but the formal test result is not reported; Section 2.2 references but does not show the test output.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Predictive Significance of CD276/B7-H3 Expression in Baseline Biopsies of Advanced Prostate Carcinoma." pith.science (2026). https://pith.science/paper/G6LNNS7M

@misc{pith2026250809373,
  author       = {Pith},
  title        = {Pith review of: Predictive Significance of CD276/B7-H3 Expression in Baseline Biopsies of Advanced Prostate Carcinoma},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/G6LNNS7M}},
  note         = {Machine review of arXiv:2508.09373}
}
read the original abstract

At the time of diagnosis, prostate cancer can appear deceptively mild or already display signs of widespread disease. Predicting long-term outcomes is often uncertain. This research focused on measuring CD276/B7-H3, an immune checkpoint protein linked to tumor development, in diagnostic tissue samples from 248 men. Participants included both those with cancer confined to the prostate and those with confirmed metastases. Analysis showed that patients with metastatic disease were more likely to exhibit increased B7-H3 levels. Strong expression of this marker was associated with shorter survival times and was observed alongside higher PSA concentrations and greater tumor aggressiveness based on Gleason grading. These trends remained consistent even when other prognostic factors were taken into account. The results suggest that assessing B7-H3 during the initial biopsy could help clinicians identify high-risk patients earlier. This marker may also represent a new target for treatment strategies in advanced prostate cancer.

Figures

Figures reproduced from arXiv: 2508.09373 by the authors.

Figure 1
Figure 1. Schoenfeld residuals for B7-H3 are plotted against event time to assess the proportional hazards [PITH_FULL_IMAGE:figures/full_fig_p008_1.png] view at source ↗
Figure 2
Figure 2. This plot displays the influence of each individual patient on the estimated B7-H3 coefficient in [PITH_FULL_IMAGE:figures/full_fig_p009_2.png] view at source ↗
Figure 3
Figure 3. The trace plot displays the evolution of the mean and standard deviation of imputed values for each [PITH_FULL_IMAGE:figures/full_fig_p010_3.png] view at source ↗
Figures from the paper (5 more)
Figure 4
Figure 4. Figure 4: Visual diagnostics for missingness. 11 [PITH_FULL_IMAGE:figures/full_fig_p011_4.png]
Figure 5
Figure 5. Figure 5: Kaplan–Meier survival curves for metastatic patients, stratified by B7-H3 expression. Patients with [PITH_FULL_IMAGE:figures/full_fig_p013_5.png]
Figure 6
Figure 6. Figure 6: Comparison of B7-H3 expression frequencies in metastatic and localized prostate cancer cohorts. [PITH_FULL_IMAGE:figures/full_fig_p014_6.png]
Figure 7
Figure 7. Figure 7: Box-and-whisker plot of PSA values among metastatic patients, broken down by B7-H3 expression. [PITH_FULL_IMAGE:figures/full_fig_p015_7.png]
Figure 8
Figure 8. Figure 8: Predicted overall survival from the Weibull model, showing a faster decline in patients with high [PITH_FULL_IMAGE:figures/full_fig_p017_8.png]

Discussion (0). Sign in to comment.

Forward citations

Cited by 3 Pith papers

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score.

  1. Modeling Educational Performance Using School Demographics and Teacher Characteristics

    stat.ME 2026-06 unverdicted novelty 6.0 of 10

    Introduces Adaptive Weighted Group Fused LASSO estimator with ADMM algorithm and asymptotic guarantees, demonstrated on Alabama school math proficiency data.

  2. Obesity and Sociodemographic Factors in Luminal Breast Cancer

    q-bio.QM 2026-05 unverdicted novelty 3.0 of 10

    Higher BMI and African ancestry independently associate with Luminal B breast cancer, with BMI partially mediating the ancestry link in a cohort of 3,538 patients.

  3. Optimal Harvesting under Stochastic Control: HJB Equation and Feynman-Kac Representation

    math.OC 2026-06 unverdicted novelty 2.0 of 10

    Applies standard HJB and Feynman-Kac methods to stochastic harvesting models and claims they are consistent for policy design.

Reference graph

Works this paper leans on

67 extracted references · 56 canonical work pages · cited by 3 Pith papers

  1. [1]

    Amori, G., Sugawara, E., Shigematsu, Y., Akiya, M., Kunieda, J., Yuasa, T., Yamamoto, S., Yonese, J., Takeuchi, K., and Inamura, K. (2021). Tumor b7-h3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer. Prostate Cancer and Prostatic Diseases , 24:767--774

    work page 2021

  2. [2]

    Benzon, B., Zhao, S., Haffner, M., Takhar, M., Erho, N., Yousefi, K., Hurley, P., Bishop, J., Tosoian, J., Ghabili, K., et al. (2017a). Correlation of b7-h3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate cancer and prostatic diseases , 20(1):28--35

    work page

  3. [3]

    G., Haffner, M

    Benzon, B., Zhao, S. G., Haffner, M. C., Takhar, M., Erho, N., and Yousefi, K. (2017b). Correlation of b7-h3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer and Prostatic Diseases , 20:28--35

    work page

  4. [4]

    E., Finn, E., Sykora, P., Lynch, V

    Bulls, S. E., Finn, E., Sykora, P., Lynch, V. J., Pramanik, P., Glaberman, S., and Chiari, Y. (2025). Assessing cometchip technology for dna damage studies in non-model species: distinct uv-induced responses in turtles and mammals. BMC Research Notes , 18(1):1--7

    work page 2025

  5. [5]

    R., Purvis, I

    Castellanos, J. R., Purvis, I. J., Labak, C. M., Guda, M. R., Tsung, A. J., and Velpula, K. K. (2017). B7-h3 role in the immune landscape of cancer. American Journal of Clinical and Experimental Immunology , 6:66--75

    work page 2017

  6. [6]

    I., Ni, J., Lau, J

    Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., and Liu, D. (2001). B7-h3: a costimulatory molecule for t cell activation and ifn-gamma production. Nature Immunology , 2:269--274

    work page 2001

  7. [7]

    A., Pramanik, P., Marbut, S

    Dasgupta, S., Acharya, S., Khan, M. A., Pramanik, P., Marbut, S. M., Yunus, F., Galeas, J. N., Singh, S., Singh, A. P., and Dasgupta, S. (2023). Frequent loss of cacna1c, a calcium voltage-gated channel subunit is associated with lung adenocarcinoma progression and poor prognosis. Cancer Research , 83(7\_Supplement):3318--3318

    work page 2023

  8. [8]

    Fan, X., Huang, J., Hu, B., Zhou, J., and Chen, L. (2023). Tumor-expressed b7-h3 promotes vasculogenic mimicry formation rather than angiogenesis in non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology , 149(11):8729--8741

    work page 2023

Show all 67 references
  1. [9]

    Guo, Y., Wang, X., Zhang, C., Chen, W., Fu, Y., Yu, Y., Chen, Y., Shao, T., Zhang, J., and Ding, G. (2025). Tumor immunotherapy targeting b7-h3: From mechanisms to clinical applications. ImmunoTargets and Therapy , pages 291--320

    2025

  2. [10]

    L., Vikramdeo, K

    Hertweck, K. L., Vikramdeo, K. S., Galeas, J. N., Marbut, S. M., Pramanik, P., Yunus, F., Singh, S., Singh, A. P., and Dasgupta, S. (2023). Clinicopathological significance of unraveling mitochondrial pathway alterations in non-small-cell lung cancer. The FASEB Journal , 37(7):e23018

    2023

  3. [11]

    Hua, L., Polansky, A., and Pramanik, P. (2019). Assessing bivariate tail non-exchangeable dependence. Statistics & Probability Letters , 155:108556

    2019

  4. [12]

    Inamura, K., Amori, G., Yuasa, T., Yamamoto, S., Yonese, J., and Ishikawa, Y. (2019). Relationship of b7-h3 expression in tumor cells and tumor vasculature with foxp3+ regulatory t cells in renal cell carcinoma. Cancer Management and Research , 11:7021--7030

    2019

  5. [13]

    Inamura, K., Takazawa, Y., Inoue, Y., Yokouchi, Y., Kobayashi, M., and Saiura, A. (2018). Tumor b7-h3 (cd276) expression and survival in pancreatic cancer. Journal of Clinical Medicine , 7:172

    2018

  6. [14]

    P., Sarkar, C., and Chakroborty, D

    Kakkat, S., Pramanik, P., Singh, S., Singh, A. P., Sarkar, C., and Chakroborty, D. (2023). Cardiovascular complications in patients with prostate cancer: Potential molecular connections. International Journal of Molecular Sciences , 24(8):6984

    2023

  7. [15]

    Kang, F.-b., Wang, L., Jia, H.-c., Li, D., Li, H.-j., Zhang, Y.-g., and Sun, D.-x. (2015). B7-h3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via jak2/stat3/slug signaling pathway. Cancer cell international , 15(1):45

    2015

  8. [16]

    Khan, M., Acharya, S., Anand, S., Sameeta, F., Pramanik, P., Keel, C., Singh, S., Carter, J., Dasgupta, S., and Singh, A. (2023a). Myb exhibits racially disparate expression, clinicopathologic association, and predictive potential for biochemical recurrence in prostate cancer,...

    2023

  9. [17]

    A., Acharya, S., Anand, S., Sameeta, F., Pramanik, P., Keel, C., Singh, S., Carter, J

    Khan, M. A., Acharya, S., Anand, S., Sameeta, F., Pramanik, P., Keel, C., Singh, S., Carter, J. E., Dasgupta, S., and Singh, A. P. (2023b). Myb exhibits racially disparate expression, clinicopathologic association, and predictive potential for biochemical recurrence in prostat...

  10. [18]

    A., Acharya, S., Kreitz, N., Anand, S., Sameeta, F., Pramanik, P., Keel, C., Singh, S., Carter, J., Dasgupta, S., et al

    Khan, M. A., Acharya, S., Kreitz, N., Anand, S., Sameeta, F., Pramanik, P., Keel, C., Singh, S., Carter, J., Dasgupta, S., et al. (2024). Mp60-05 myb exhibits racially disparate expression and clinicopathologic association and is a promising predictor of biochemical recurrence...

    2024

  11. [19]

    Liu, Y., Vlatkovic, L., Saeter, T., Servoll, E., Waaler, G., and Nesland, J. M. (2012). Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive b7-h3-expressing cell population? International Journal of Urology , 19:749--756

    2012

  12. [20]

    Ma, Z., Yang, J., Jia, W., Li, L., Li, Y., Hu, J., Luo, W., Li, R., Ye, D., and Lan, P. (2025). Histone lactylation-driven b7-h3 expression promotes tumor immune evasion. Theranostics , 15(6):2338

    2025

  13. [21]

    Maki, E., Glimm, T., Pramanik, P., Chiari, Y., and Kiskowski, M. (2025). New approaches for capturing and estimating variation in complex animal color patterns from digital photographs: application to the eastern box turtle (terrapene carolina). PeerJ , 13:e19690

    2025

  14. [22]

    A., Lu, J., Kaur, H

    Mendes, A. A., Lu, J., Kaur, H. B., Zheng, S. L., Xu, J., Hicks, J., Weiner, A. B., Schaeffer, E. M., Ross, A. E., Balk, S. P., et al. (2022). Association of b7-h3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer...

    2022

  15. [23]

    Mielcarska, S., Dawidowicz, M., Kula, A., Kiczmer, P., Skiba, H., Krygier, M., Chraba \'n ska, M., Piecuch, J., Szrot, M., Ochman, B., et al. (2023). B7h3 role in reshaping immunosuppressive landscape in msi and mss colorectal cancer tumours. Cancers , 15(12):3136

    2023

  16. [24]

    D., Likasitwatanakul, P., Toye, E., Hwang, J

    Miller, C. D., Likasitwatanakul, P., Toye, E., Hwang, J. H., and Antonarakis, E. S. (2024). Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment. Expert Review of Anticancer Therapy , 24(11):1085--1100

    2024

  17. [25]

    Mortezaee, K. (2023). B7-h3 immunoregulatory roles in cancer. Biomedicine & Pharmacotherapy , 163:114890

    2023

  18. [26]

    E., Emaldi, M., Guldvik, I

    Nunes-Xavier, C. E., Emaldi, M., Guldvik, I. J., Ramberg, H., Task \'e n, K. A., M landsmo, G. M., Fodstad, ., Llarena, R., Pulido, R., and L \'o pez, J. I. (2023). Correlation of expression of major vault protein with androgen receptor and immune checkpoint protein b7-h3, and...

    2023

  19. [27]

    C., and Zang, X

    Picarda, E., Ohaegbulam, K. C., and Zang, X. (2016). Molecular pathways: targeting b7-h3 (cd276) for human cancer immunotherapy. Clinical Cancer Research , 22:3425--3431

    2016

  20. [28]

    Polansky, A. M. and Pramanik, P. (2021). A motif building process for simulating random networks. Computational Statistics & Data Analysis , 162:107263

    2021

  21. [29]

    Pramanik, P. (2016). Tail non-exchangeability . Northern Illinois University

    2016

  22. [30]

    Pramanik, P. (2020). Optimization of market stochastic dynamics. SN Operations Research Forum , 1(4):31

    2020

  23. [31]

    Pramanik, P. (2021a). Effects of water currents on fish migration through a feynman-type path integral approach under 8/3 liouville-like quantum gravity surfaces. Theory in Biosciences , 140(2):205--223

  24. [32]

    Pramanik, P. (2021b). Optimization of Dynamic Objective Functions Using Path Integrals . PhD thesis, Northern Illinois University

  25. [33]

    Pramanik, P. (2022a). On lock-down control of a pandemic model. arXiv preprint arXiv:2206.04248

    arXiv

  26. [34]

    Pramanik, P. (2022b). Stochastic control of a sir model with non-linear incidence rate through euclidean path integral. arXiv preprint arXiv:2209.13733

    arXiv

  27. [35]

    Pramanik, P. (2023a). Consensus as a nash equilibrium of a stochastic differential game. European Journal of Statistics , 3:10--10

  28. [36]

    Pramanik, P. (2023b). Optimal lock-down intensity: A stochastic pandemic control approach of path integral. Computational and Mathematical Biophysics , 11(1):20230110

  29. [37]

    Pramanik, P. (2023c). Path integral control in infectious disease modeling. arXiv preprint arXiv:2311.02113

    arXiv

  30. [38]

    Pramanik, P. (2023d). Path integral control of a stochastic multi-risk sir pandemic model. Theory in Biosciences , pages 1--36

  31. [39]

    Pramanik, P. (2024a). Dependence on tail copula. J , 7(2):127--152

  32. [40]

    Pramanik, P. (2024b). Estimation of optimal lock-down and vaccination rate of a stochastic sir model: A mathematical approach. European Journal of Statistics , 4:3--3

  33. [41]

    Pramanik, P. (2024c). Measuring asymmetric tails under copula distributions. European Journal of Statistics , 4:7--7

  34. [42]

    Pramanik, P. (2024d). On estimation of function-on-function regression kernels with brownian berkson errors

  35. [43]

    Pramanik, P. (2024e). Stochastic control in determining a soccer player’s performance. J. Compr. Pure Appl. Math , 2:111

  36. [44]

    Pramanik, P. (2025a). An optimal level of stubbornness to win a soccer match. arXiv preprint arXiv:2501.18050

    arXiv

  37. [45]

    Pramanik, P. (2025b). Stubbornness as control in professional soccer games: A bppsde approach. Mathematics , 13(3):475

  38. [46]

    L., and Ghanam, R

    Pramanik, P., Boone, E. L., and Ghanam, R. A. (2024). Parametric estimation in fractional stochastic differential equation. Stats , 7(3):745

    2024

  39. [47]

    and Dong, L

    Pramanik, P. and Dong, L. (2025a). Impact of random monetary shock: a keynesian case. arXiv preprint arXiv:2505.00800

    arXiv

  40. [48]

    and Dong, L

    Pramanik, P. and Dong, L. (2025b). Strategic complementarities due to monetary shock under sticky price. European Journal of Statistics , 5:9--9

  41. [49]

    Pramanik, P., Graff, J., and Decaro, M. (2025a). On factors influencing consumer preference in pipeline stages: an experiment. arXiv preprint arXiv:2501.03418

    arXiv

  42. [50]

    Pramanik, P., Graff, J., and Decaro, M. (2025b). Strategies to increase pipeline status: A case study from eclinical data. European Journal of Statistics , 5:3--3

  43. [51]

    and Maity, A

    Pramanik, P. and Maity, A. K. (2024). Bayes factor of zero inflated models under jeffereys prior. arXiv preprint arXiv:2401.03649

    2024 arXiv

  44. [52]

    and Polansky, A

    Pramanik, P. and Polansky, A. M. (2020). Motivation to run in one-day cricket. arXiv preprint arXiv:2001.11099

    2020 arXiv

  45. [53]

    and Polansky, A

    Pramanik, P. and Polansky, A. M. (2021). Optimal estimation of brownian penalized regression coefficients. arXiv preprint arXiv:2107.02291

    2021 arXiv

  46. [54]

    and Polansky, A

    Pramanik, P. and Polansky, A. M. (2023a). Optimization of a dynamic profit function using euclidean path integral. SN Business & Economics , 4(1):8

  47. [55]

    and Polansky, A

    Pramanik, P. and Polansky, A. M. (2023b). Scoring a goal optimally in a soccer game under liouville-like quantum gravity action. Operations Research Forum , 4(3):66

  48. [56]

    and Polansky, A

    Pramanik, P. and Polansky, A. M. (2023c). Semicooperation under curved strategy spacetime. The Journal of Mathematical Sociology , pages 1--35

  49. [57]

    and Polansky, A

    Pramanik, P. and Polansky, A. M. (2024). Motivation to run in one-day cricket. Mathematics , 12(17):2739

    2024

  50. [58]

    V., Nguyen, T., Li, Z., Yang, Y., Duong, J., and Wang, Y

    Prasad, D. V., Nguyen, T., Li, Z., Yang, Y., Duong, J., and Wang, Y. (2004). Murine b7-h3 is a negative regulator of t cells. Journal of Immunology , 173:2500--2506

    2004

  51. [59]

    J., Sheinin, Y., Lohse, C

    Roth, T. J., Sheinin, Y., Lohse, C. M., Kuntz, S. M., Frigola, X., and Inman, B. A. (2007). B7-h3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Research , 67:7893--7900

    2007

  52. [60]

    B., and et al

    Seaman, S., Zhu, Z., Saha, S., Zhang, X.-M., Yang, M.-Y., Hilton, M. B., and et al. (2017). Eradication of tumors through simultaneous ablation of cd276/b7-h3-positive tumor cells and tumor vasculature. Cancer Cell , 31:501--515.e8

    2017

  53. [61]

    K., Gajewska, B

    Suh, W. K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., and Dawicki, W. (2003). The b7 family member b7-h3 preferentially down-regulates t helper type 1-mediated immune responses. Nature Immunology , 4:899--906

    2003

  54. [62]

    and Pramanik, P

    Valdez, I. and Pramanik, P. (2025a). Association between obesity, race, and luminal subtypes of breast cancer. European Journal of Statistics , 5:12--12

  55. [63]

    and Pramanik, P

    Valdez, I. and Pramanik, P. (2025b). Exploring the interplay of adiposity, ethnicity, and hormone receptor profiles in breast cancer subtypes. arXiv preprint arXiv:2507.21348

    arXiv

  56. [64]

    Vikramdeo, K., Anand, S., Sudan, S., Pramanik, P., Singh, S., Godwin, A., Singh, A., and Dasgupta, S. (2024a). Abstract po3-16-05: Mitochondrial dna mutation detection in tumors and circulating extracellular vesicles of triple negative breast cancer patients for biomarker deve...

  57. [65]

    Vikramdeo, K., Anand, S., Sudan, S., Pramanik, P., Singh, S., Godwin, A., Singh, A., and Dasgupta, S. (2024b). Mitochondrial dna mutation detection in tumors and circulating extracellular vesicles of triple negative breast cancer patients for biomarker development. In CANCER R...

  58. [66]

    S., Anand, S., Sudan, S

    Vikramdeo, K. S., Anand, S., Sudan, S. K., Pramanik, P., Singh, S., Godwin, A. K., Singh, A. P., and Dasgupta, S. (2023). Profiling mitochondrial dna mutations in tumors and circulating extracellular vesicles of triple-negative breast cancer patients for potential biomarker de...

    2023

  59. [67]

    H., Al-Ahmadie, H

    Zang, X., Thompson, R. H., Al-Ahmadie, H. A., Serio, A. M., Reuter, V. E., and Eastham, J. A. (2007). B7-h3 and b7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proceedings of the National Academy of Sciences , 104:19458--19463

    2007

Pith tools

Reviewed August 5, 2026 · model on record in the stance chip above.